top of page
allissa_long.jpg

Allissa Long, PharmD, BCACP

Assistant Professor, University of Saint Joseph

Dr. Allissa Long is an Assistant Professor of Pharmacy Practice at the University of Saint Joseph in West Hartford, Connecticut. Dr. Long earned her Doctor of Pharmacy from Western New England University College of Pharmacy and Health Sciences in Springfield, Massachusetts. She completed her PGY1 at UConn John Dempsey Hospital and her PGY2 in ambulatory care/academia at Veterans Health Indiana and Butler University. Her clinical specialties include outpatient primary care disease state management and chronic kidney disease.

Disclosures: 

 

The following planners and presenters have disclosed a financial relationship with an ineligible company:

  • Allissa Long, PharmD, BCACP

  • Wendy St Peter, FCCP, FASN, FNKF - Consultant [GSK]

 

There are no conflicts of interest or financial relationships with an ineligible company that have been disclosed by the rest of the planners and presenters of this learning activity.

All relevant financial relationships have been mitigated.

Presenting Modules:

 

CKD Treatment: Addressing Kidney and Cardiometabolic Outcomes Part 4: Mineralocorticoid Receptor Antagonists

A new non-steroidal mineralocorticoid receptor antagonist (MRA), finerenone, is FDA-approved for kidney and heart protection in patients with type 2 diabetes. In this module, we will be introducing the different MRAs that are commercially available and discussing the evidence to support their use in patients with kidney disease. This will include a focus on criteria for use of finerenone in our patients with type 2 diabetes, and the patient-specific considerations of when to use this medication.

AKHOMM is fiscally sponsored by the Alliance for Integrated Medication Management (AIMM), a non-profit organization.

All content © Advancing Kidney Health through Optimal Medication Management 2024

  • Twitter
  • LinkedIn
bottom of page